Traditional prostate cancer risk factors do not predict hormone therapy benefit, study fin

Traditional prostate cancer risk factors do not predict hormone therapy benefit, study finds. A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery can help identify patients who are more likely to have worse outcomes, they do not predict who will benefit more from adding hormone therapy to postoperative radiation.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery can help identify patients who are more likely to have worse outcomes, they do not predict who will benefit more from adding hormone therapy to postoperative radiation.

• Ponto de atenção: traditional.
• Ponto de atenção: prostate.
• Ponto de atenção: cancer.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.